Literature DB >> 6728293

5-Hydroxytryptamine (5-HT)-dependent myoclonus in guinea pigs is induced through brainstem 5-HT-1 receptors.

G Luscombe, P Jenner, C D Marsden.   

Abstract

Myoclonic jerking in guinea pigs originates from the brainstem. Indole-containing 5-hydroxytryptamine (5-HT) agonists, but not piperazine-containing 5-HT agonists, induced myoclonus in guinea pigs at pharmacologically relevant doses. Guinea pig brainstem preparations possessed specific binding sites for [3H]5-HT but specific [3H]spiperone binding was low and inconsistent. 5-HT-1 receptors appear to predominate in this tissue. High affinity [3H]5-HT binding was potently displaced by indole-containing 5-HT agonists but only weakly displaced by piperazine-containing 5-HT agonists. The [3H]5-HT specific binding site in guinea pig brainstem responsible for the induction of indoleamine-dependent myoclonus has the characteristics of a 5-HT-1 receptor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6728293     DOI: 10.1016/0304-3940(84)90029-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  3 in total

1.  Effects of repeated administration of the monoamine oxidase inhibitor phenelzine on the discriminability of d-lysergic acid diethylamide (LSD) and 1-(m-trifluoromethylphenyl) piperazine (TFMPP).

Authors:  K A Cunningham; B A Carroll; J B Appel
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Autoradiographic mapping of 5-HT1 receptors in the guinea-pig brain with particular reference to the 5-HT1D receptor sites.

Authors:  C del Arco; I Galende; A Pazos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

3.  Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors.

Authors:  G A Gudelsky; J I Koenig; H Jackman; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.